Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.
A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.
Vandenbark
A A
AA
Veterans Affairs Medical Center, Portland, Oregon 97201, USA.
Chou
Y K
YK
Whitham
R
R
Mass
M
M
Buenafe
A
A
Liefeld
D
D
Kavanagh
D
D
Cooper
S
S
Hashim
G A
GA
Offner
H
H
D000328:Adult; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D059811:HLA-DRB1 Chains; D006801:Humans; D016233:Immunotherapy, Active; D016753:Interleukin-10 / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology*; D010865:Pilot Projects; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D004676:Myelin Basic Protein; D010446:Peptide Fragments; D016693:Receptors, Antigen, T-Cell, alpha-beta; D014612:Vaccines; D016753:Interleukin-10